ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1462

Expert Consensus for Performing Right Heart Catheterization in Suspicion of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis: A Delphi Consensus Study with Cluster Analysis From the Eposs Group

Jerome Avouac1, Dörte Huscher2, Daniel Furst3, Oliver Distler4 and Yannick Allanore5, 1Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 2German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 3Div of Rheumatology, UCLA Medical School, Los Angeles, CA, 4Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: pulmonary complications and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Pulmonary hypertension (PH) has emerged as a critical cause of death in systemic sclerosis (SSc). Recent data have highlighted the poorer outcomes of SSc associated PAH as compared to the idiopathic forms. Therefore, the management of SSc patients at risk of PAH risk must be improved to allow early diagnosis. However, there is presently no guideline regarding the parameters that should lead the physician to perform right heart catheterization, the only tool unequivocally establishing the correct diagnosis. Our aim was, by consensus, to identify the most appropriate indications for RHC in patients with SSc.

Methods: A three-stage Delphi exercise involving worldwide PH experts was designed to answer the following question: “based on which parameters, performed on the basis of an annual screening of SSc patients in clinical practice, do you decide to refer patients for RHC?”. The Delphi exercise was performed between March 2011 and December 2011.

The aim of the first stage was to obtain a comprehensive list of domains and tools to be considered before referring a SSc patient for RHC. This list combined evidence-based indications extracted from published reports on SSc-PH and expert opinions. For the second stage, experts were asked to rate each item proposed in the list, using a 5-point scale (1 indicates “not important/appropriate at all” and 5 indicates “very important/appropriate”). For the third stage, experts were asked to rate the items accepted after the second round, using the same 5-point scale. After each of stages 2 and 3, the number of domains and tools was reduced according to a cluster analysis. The number of clusters was generated by an automatic cluster algorithm using Bayes information criterion.

Results: 77 experts were contacted by e-mail to participate in this Delphi procedure. 47 (61%) participated in stage 1, 50 (65% of the 77) in stage 2, and 48 (62% of the 77) in stage 3. The list obtained after the first stage consisted on 7 domains (clinical, biomarkers, pulmonary function tests, echocardiography, cardiopulmonary exercise, imaging and EKG) containing a total of 142 tools. Cluster analysis performed after the second stage allowed discarding of 63 of the 142 initial tools. Cluster analysis performed after stage 3 reduced the EPOSS instrument to 3 domains containing 8 items (see table).

Domains

Tools

Mean ratings

(5-point scale)

Clinical tools

*Progressive dyspnea over the last 3 months

*Unexplained dyspnea

*Worsening in WHO dyspnea functional class

*Any finding on physical examination suggestive of elevated right heart pressures (Jugular venous distension, accentuated S2, TR murmur, etc)

*Any sign of right heart failure

4.4

4.3

4.4

4.4

4.8

Echocardiography

* sPAP>45 mmHg

* Dilation of right ventricle

4.3

4.3

Pulmonary function tests

* DLCO<50% without pulmonary fibrosis

4.4

Conclusion: Among experts in PH-SSc, a core set of indications for clinical practice has been defined to refer SSc patients to RHC in case of PH suspicion. This EPOSS instrument is the first expert guidelines for PH detection that is based on validated consensus methods. Although these indications are recommended by this expert group, it is an interim tool. It will be necessary to formally validate and extend the EPOSS instrument in further studies, both for clinical practice and in terms of additional research.


Disclosure:

J. Avouac,

Actelion Pharmaceuticals US,

2,

Pfizer Inc,

2;

D. Huscher,
None;

D. Furst,

Abbott, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB,

2,

Abbott, Actelion, Amgen, BMS, BiogenIdec, Centocor, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB,

5,

Abbott, Actelion, UCB ,

8;

O. Distler,

Actelion, Bayer. Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4 D Science and Active Biotec ,

2,

Actelion, Bayer. Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4 D Science and Active Biotec ,

5,

Actelion, Pfizer and Ergonex,

8;

Y. Allanore,

Actelion Pharmaceuticals US,

2,

Pfizer Inc,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expert-consensus-for-performing-right-heart-catheterization-in-suspicion-of-pulmonary-arterial-hypertension-associated-with-systemic-sclerosis-a-delphi-consensus-study-with-cluster-analysis-from-the/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology